Axl inhibitor-mediated reprogramming of the myeloid compartment of the <i>in vitro</i> tumor microenvironment is influenced by prior targeted therapy treatment.

ABSTRACT: Axl, a member of the receptor tyrosine kinase family comprised of Tyro3, Axl, and MerTK, is a promising cancer therapeutic target actively under clinical investigation. Axl is understood to be a dual target in cancer to (1) prevent tumor cell growth and invasion and (2) potentiate anti-tumor immunity. This immunity is characterized by myeloid cell activation and downstream recruitment and activation of anti-tumor T cells. However, the ways by which Axl inhibition promotes myeloid cell activation in the tumor microenvironment are incompletely understood. There is thus a need to understand the effects of Axl inhibition on myeloid cells in the context of the broader tumor microenvironment. Here, we developed a human in vitro model system using primary human monocyte-derived macrophages

SUBMITTER: Datta A 

PROVIDER: S-EPMC12176863 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature